Capsida unveils new next-gen gene therapy production site

July 27, 2021

In-house center eliminates the need for a contract manufacturer, company says

Capsida Biotherapeutics Inc., a fully-integrated biotech company that is creating targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, is opening up its 15,000 square-foot manufacturing facility in Thousand Oaks, CA. The good manufacturing practice (GMP) manufacturing center features two ballroom production suites, a fill suite and an in-house quality-control laboratory.

The gene therapy company’s expertise lies in AAV engineering, cargo development and optimization, translational biology, early capsid manufacturability, clinical development and state-of-the-art manufacturing.

"One of our key strategic priorities at Capsida is to create therapies that can be manufactured consistently and rapidly while maintaining the highest quality," says Rayne Waller, Capsida Biotherapeutics’ chief manufacturing officer. "Our new manufacturing facility eliminates the dependence on contract manufacturing, which will allow us to bring products seamlessly from discovery into clinical studies faster. In addition, our robust process development and analytical capabilities are cornerstones of our ability to reliably produce high quality gene therapies to meet worldwide regulatory expectations."